AMENDMENTS TO THE CLAIMS

Listing of claims:

1. (Currently Amended) A sugar chain-altered antibody (anti-HM1.24 antibody) against HM1.24 antigen, wherein the antibody comprises a sugar chain which includes N-glycoside-linked sugar which has a basic structure

Manβ1-4GlcNAcβ1-4GlcNAc-PA

wherein said sugar chain does not contain α 1,6 core but contains a bisecting N-acetylglucosamine (GlcNAc) which is bound with a β 1,4-linkage on the mannose (Man) of the basic structure.

- 2. (Original) The antibody (anti-HM1.24 antibody) against HM1.24 antigen according to claim 1 in which the alteration of sugar chains resulted in enhanced antibody-dependent cellular cytotoxicity (ADCC).
- 3. (Previously Presented) The antibody according to claim 1 in which said antibody is a monoclonal antibody.
- 4. (Previously Presented) The antibody according to claim 1 in which said antibody is a chimeric antibody.
- 5. (Previously Presented) The antibody according to claim 1 in which said antibody is a humanized antibody.
 - 6–8 (Cancelled)

- 9. (Currently Amended) An antibody composition comprising anti-HM1.24 antibody having a sugar chain according to claim 1, wherein of all sugar chains on said antibody the relative ratio of all fucose-free sugar chains is 30% or more.
- 10. (Withdrawn-Currently Amended) A method of producing said antibody according to claim [[6]] 1 which method comprises culturing cells deficient in fucose-adding ability having introduced therein a nucleic acid encoding an antibody (anti-HM1.24 antibody) against HM1.24 antigen, and harvesting said antibody from said culture.
- 11. (Withdrawn) A method of producing said antibody according to claim 7 which method comprises culturing a host cell having introduced therein a nucleic acid encoding N-acetylglucosaminyl transferase III (GnTIII), and harvesting said antibody from said culture.
- 12. (Withdrawn) A method of producing said antibody according to claim 8 which method comprises culturing cells deficient in fucose-adding ability having introduced therein a nucleic acid encoding N-acetylglucosaminyl transferase III (GnTIII), and harvesting said antibody from said culture.
- 13. (New) The sugar chain-altered antibody of claim 1, wherein the N-glycoside-linked sugar which does not contain $\alpha 1,6$ core but contains a bisecting N-acetylglucosamine (GlcNAc) which is bound with a $\beta 1,4$ -linkage, has the following structure:

$$\frac{\text{GlcNAc}\beta 1 - 2\text{Man}\alpha 1}{6} \\ \frac{\text{GlcNAc}\beta 1 - 4\text{ Man}\beta 1 - 4\text{GlcNAc}\beta 1 - 4\text{GlcNAc-PA}}{3} \\ \frac{3}{6} \\ \frac{3$$

14. (New) The sugar chain-altered antibody of claim 1, wherein the N-glycoside-linked sugar which does not contain α 1,6 core but contains a bisecting N-acetylglucosamine (GlcNAc) which is bound with a β 1,4-linkage, has the following structure:

$$Gal\beta 1\text{-}4\ GlcNAc\beta 1\ -\ 2Man\alpha 1 \\ GlcNAc\beta 1\ -\ 4\ Man\beta 1\text{-}4GlcNAc\beta 1\text{-}4GlcNAc\text{-}PA \\ GlcNAc\beta 1\ -\ 2Man\alpha 1 \\ \end{array}.$$

15. (New) The sugar chain-altered antibody of claim 1, wherein the N-glycoside-linked sugar which does not contain α 1,6 core but contains a bisecting N-acetylglucosamine (GlcNAc) which is bound with a β 1,4-linkage, has the following structure:

$$GlcNAc\beta1 - 2Man\alpha1 \searrow 6$$

$$GlcNAc\beta1 - 4 Man\beta1 - 4GlcNAc\beta1 - 4GlcNAc-PA$$

$$Gal\beta1 - 4 GlcNAc\beta1 - 2Man\alpha1 \nearrow 3$$